Seqirus is First-to-Market with U.S. 2019/20 Influenza Vaccines

Seqirus announced it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the United States for the 2019/20 influenza season. Seqirus expects to distribute over 50 million doses to the U.S. market this year, with the majority of doses coming from its adjuvanted and cell-based technology platforms.

The company will provide FLUAD® (Influenza Vaccine, Adjuvanted), the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older; and FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the most widely available cell-based influenza vaccine in the country, available for those aged four and older.

FLUCELVAX® QUADRIVALENT was manufactured for the 2019/20 influenza season using cell-based candidate vaccine virus (CVV) for all four influenza strains recommended by the World Health Organization (WHO).

"As the only global vaccine company solely dedicated to the prevention of influenza, Seqirus is proud to bring our broad portfolio of innovative vaccines to customers as part of our leading role on the front line of influenza prevention," said Brent MacGregor, Senior Vice President, Commercial Operations at Seqirus. "We work closely with partners all year long to build on our track record of reliable supply, and we're proud to be the first influenza vaccine manufacturer to ship product to the U.S. market during this influenza season."

The Seqirus 2019/20 influenza vaccine portfolio also includes AFLURIA® QUADRIVALENT (Influenza Vaccine), an egg-based quadrivalent influenza vaccine. The complete portfolio of influenza vaccines provides a range of options for people six months of age and older, four years of age and older, and 65 years of age and older, presented in pre-filled syringes as well as multi-dose vials.

Seqirus also distributes Rapivab® (peramivir injection), the only one-dose intravenous antiviral treatment for acute uncomplicated influenza for people two years of age and older.

"Vaccination can save millions of people," said Gregg Sylvester, M.D., Vice President of Medical Affairs at Seqirus.1 "In recent years, we have introduced vaccine technology designed to deliver on our commitment to protect people and communities from seasonal influenza."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com